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Bruno Masquelier*, Georges Reniers**
In sub-Saharan Africa, the majority of people living with HIV are women. Yet the number of 
AIDS-related deaths in this region is higher among men and the gender gap in life expectancy 
has expanded in recent years. Bruno Masquelier and Georges Reniers explain the reasons 
behind this paradox. 
AIDS and the gender gap in life 
expectancy in Africa
The HIV-AIDS epidemic is still taking many lives each 
year. In 2016, a million people died from the disease, and 
almost three-quarters of  these deaths occurred in sub-
Saharan Africa (73%) [1]. Recent trends are nonetheless 
encouraging; the number of  AIDS related deaths in the 
region has halved since 2005. The expansion of  
antiretroviral treatment programs has been an important 
factor in these mortality declines, and women appear to 
have benefitted most from the treatment scale-up: the 
number of  AIDS related deaths among women aged 15 
and above declined by 58% between 2005 and 2016, and 
by 43% among men. As a result, women now account 
for the minority (47%) of  AIDS deaths in Africa [1], yet 
remain overrepresented (59%) among people living with 
HIV in the region. Women also continue to lose more 
years of  life expectancy to AIDS than men. This article 
explores explanations for these trends in HIV prevalence 
and AIDS mortality, and the apparent gender paradoxes 
that they entail. 
HIV prevalence is everywhere 
higher among women
According to Demographic and Health Surveys (DHS) 
conducted between 2006 and 2016, HIV prevalence (the 
proportion or percentage of  adults infected with HIV) is 
higher among women than among men in all countries 
of  sub-Saharan Africa. Based on data from the 30 surveys 
used to draw the map in Figure 1, the average female-to-
male prevalence ratio is 1.7. Curiously, this ratio is highest 
in the countries of  Central Africa, where HIV prevalence 
is relatively moderate. 
Source: Most recent DHS surveys. Interpretation: in Zimbabwe, 
according to the 2015 DHS survey, the female-to-male prevalence 
ratio is between 1.5 and 2.0 (it is in fact 1.6, female prevalence 
being 16.7% and male prevalence 10.5%). 
Figure 1. Female-to-male prevalence ratio of HIV 
infection at ages 15-49
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As a consequence, life expectancy at age 15 fell by 17 years 
(from 52 to 35 years [5]). In all four countries, women’s 
all-cause mortality levels remained below those of  men 
throughout the period, although the gender gap narrowed 
as mortality from HIV increased. In Zimbabwe, for 
example, the male-to-female ratio of  the probability of  
dying between ages 15 and 60 fell from 1.4 in 1985-1990 
to 1.1 in 2000-2005. Zimbabwean women aged 15 could 
expect to live 6 years longer than men in 1990-1995. By 
2005-2010, when the impact of  AIDS on adult mortality 
was most severe, women’s life expectancy advantage had 
shrunk to just over two  years. This situation was 
temporary, however, and the gender gap has widened 
again in recent years as life expectancy resumed its 
upward trend. 
The effect of treatment scale-up 
Antiretroviral therapy (ART) prevents the replication of  
the virus, improves survival and reduces the risk of  
onwards transmission. Until 2004-2005, the provision of  
ART was largely restricted to high and middle income 
countries. Since then, they have been increasingly 
provided free of  charge across the world, including sub-
Saharan Africa. The latest WHO recommendations, 
issued in 2015, state that anyone infected with HIV should 
To understand why women are overrepresented in the 
HIV-infected population, three differences between men 
and women must be considered: gender differences in 
exposure to infected partners; gender differences in 
susceptibility to infection per coital act, and finally also 
gender differences in survival after infection. Gender 
differences in exposure are linked to differences in sexual 
behaviour and to the age gap between partners. In the 
early stages of  the epidemic in Africa, transmission 
occurred mainly between prostitutes and their clients, so 
more men than women were infected [2]. As the epidemic 
became widespread, the female-to-male ratio of  infections 
increased. This is because women tend to have sexual 
partners who are older than themselves, and older partners 
are more likely to have previously contracted HIV. 
Women’s greater susceptibility to infection also plays a 
role. It is explained mainly by anatomical factors. During 
the sexual act, the risk of  infection is higher for the partner 
who is penetrated. The viral load is higher in sperm than 
in vaginal secretions, and the surface area of  the mucous 
membranes exposed to the virus is higher in women than 
men. Last, the female-to-male prevalence ratio depends 
on survival after infection. Without treatment, the risk of  
dying from AIDS increases with the age at infection, and 
women thus tend to live longer with the virus than men 
because they are infected at younger ages [3]. 
A temporary reduction in the female mortality 
advantage
The AIDS epidemic has produced a sharp increase in 
mortality, especially at adult ages. However, it is difficult 
to monitor detailed mortality trends in most African 
countries because only a small fraction of  deaths are 
officially registered. Here, we use estimates based on 
information on the survival of  siblings reported by 
women interviewed in the DHS surveys [4]. Figure 2 
shows the probability of  dying between ages 15 and 60 
(45q15) for four African countries, and compares it with 
estimates from the United Nations Population Division 
[5]. Major differences between these sources exist, which 
reflects the uncertainty around adult mortality estimation 
in African populations (Box 1). 
All four countries in Figure  2 are characterised by 
generalised HIV epidemics (i.e. more than 1% of  the 
adult population infected with HIV). HIV prevalence 
peaked in Kenya in 1996 (at 11%), in Zambia in 1997 
(16%), in Namibia in 2002 (16%) and in Zimbabwe in 
1997 (23%) [1]. Meanwhile, prevalence has fallen to 5% 
in Kenya, but remains between 12% and 14% in the three 
other countries. As a result of  its high prevalence, the 
mortality increase has been especially pronounced in 
Zimbabwe where the risk of  dying between ages 15 and 
60 more than doubled between 1985-1990 and 2000-2005. 
Box 1. The challenge of estimating AIDS- 
related mortality in sub-Saharan Africa
Surveys and censuses provide direct estimates of adult 
mortality in sub-Saharan Africa, but these data are affected 
by various sampling and non-sampling biases. For this rea-
son, the United Nations estimates are often based on 
models. At present, mortality is estimated in two stages for 
sub-Saharan African countries with a high prevalence of HIV 
[5]. First, the mortality levels of the uninfected population 
are obtained by combining child mortality trends with an 
age pattern of mortality that is expected in the absence of 
HIV. Excess mortality from AIDS is estimated using Spectrum, 
an epidemiological and demographic model developed in 
collaboration with UNAIDS [3], and subsequently added to 
the estimated non-HIV mortality. As can be seen in Figure 
2, the UN estimates are generally higher than those obtained 
from survey data, since the latter are often plagued by under-
reporting of deaths, misreporting of ages at death, and other 
errors. Note, however, that the difference between sources 
varies from one country to another: it is, for example, smal-
ler in Namibia and larger in Kenya. When the model-based 
mortality levels significantly deviate from those deduced 
from surveys and censuses, adjustments are made to obtain 
a reasonable fit. However, there are still large uncertainties 
about some of the parameters that play a key role in these 
models, such as the age pattern and sex ratio of infections, 
or, the age pattern of mortality in the uninfected population.
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start treatment as soon as possible after diagnosis. The 
sooner treatment is initiated, the greater its efficacy. In 
2016, around 53% of  HIV-infected individuals in the 
world – around 20 million people in total – were receiving 
treatment [1].
AIDS-related mortality has fallen substantially following 
the rollout of  ART. This mortality decline is, however, 
more pronounced for women than for men, which in 
turn is linked to women’s better uptake of  HIV diagnosis 
and care services. Figure 3 shows the proportions of  men 
and women who reported having ever been tested (in 
latest DHS surveys). For example, in the 2015 DHS survey 
in Zimbabwe, 80% of  women aged 15-49 reported having 
been tested, versus just 62% of  men. Thanks to the 
integration of  antenatal and HIV care (under programmes 
for the prevention of  mother-to-child transmission, 
PMTCT), women are more effectively engaged with HIV 
services [6], and HIV positive women tend to begin 
treatment earlier and adhere more closely to the 
treatment regimens.
Figure 4 presents the male and female ART coverage 
rates (based on UNAIDS estimates [1]). In a large majority 
of  countries, they are higher for women, by 15% on 
average. These treatment differences are an important 
factor in the renewed increase in the female survival 
advantage (Box 2), and therefore also explain why women 
are still overrepresented in the HIV-positive population. 
***
In sum, women generally live about five years longer 
than men, but the massive increase in AIDS-related 
mortality temporarily reduced the female survival 
advantage in eastern and southern African populations 
that are worst affected by HIV. Women lost more years 
of  life expectancy to HIV as the epidemic spread, but also 
regained more years following the expansion of  
treatment. This phenomenon is reinforced by the fact 
that PMTCT programs have facilitated the earlier 
diagnosis of  HIV among women, which improves the 
prognosis for survival. Women also adhere better to their 
treatment regimens. Nonetheless, the burden of  HIV 
mortality in terms of  the per capita life-years lost to HIV/
AIDS, remains higher for women than for men because 
of  continuing gender inequalities in exposure and 
Note: 45q15 is the probability that a person aged 15 dies before age 60. 
Sources: Demographic and Health surveys (authors’ calculations) and United Nations 
(2017) [5].
Figure 2. Adult mortality at ages 15-60 in four countries
B. Masquelier & G. Reniers, Population & Societies n° 554, INED, April 2018.
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n° 554, INED, April 2018.
Figure 4. Percentage of men and 
women infected with HIV and 
receiving treatment (in 2016)
Source: UNAIDS [1].
Figure 3. Percentage of men and 
women who have tested for HIV and 
received the result
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In sub-Saharan Africa, women account for 59% of people 
infected with HIV, but only 47% of HIV-related adult deaths. 
To understand why women are overrepresented in the HIV-
infected population, differences between men and women 
must be considered in terms of exposure to infected 
partners, susceptibility to infection per coital act, and 
survival after infection. The female life expectancy 
advantage, which contracted as the AIDS epidemic spread, 
is now increasing again since the roll-out of antiretroviral 
treatments. The burden of HIV mortality in terms of the per 
capita life-years years lost to HIV remains, however, larger 
for women than for men.  
Abstract
susceptibility, but also because women are infected at 
younger ages and face fewer competing mortality risks 
in early adulthood. In other words, one female HIV death 
will incur a greater loss in life-years lived than is the case 
for a male HIV death. 
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Box 2. The impact of antiretroviral therapy 
(ART) on survival in KwaZulu-Natal,  
South Africa
As of 2012, between a quarter and one-third of all adults of 
reproductive age were HIV-positive in KwaZulu-Natal, a 
coastal province of South Africa with one of the most severe 
HIV epidemics in the world (South African National HIV 
Prevalence, Incidence and Behaviour Survey, 2012). How-
ever, thanks to treatment scale-up, the impact of HIV on 
mortality has reversed in dramatic fashion. Based on data 
from the uMkhanyakude Health and Demographic Surveil-
lance System, life expectancy at age 20 between 2003 and 
2014 rose by 1.3 years per annum, for a total gain in adult life 
expectancy of over 15 years [7]. No other human population 
in modern history has experienced such large mortality 
reductions over a sustained period of time. 
Figure 5 shows that these life expectancy gains in KwaZulu-
Natal are almost exclusively driven by a reduction in morta-
lity from tuberculosis and HIV. The bars on the graph repre-
sent the percentage contribution of each cause of death to 
the overall adult life expectancy gains since ART became 
available. Due to high levels of comorbidity, it is difficult to 
distinguish between tuberculosis and HIV/AIDS in genera-
lized epidemics, and they jointly explain over 80% of the 
mortality reductions. As a result of the treatment scale-up, 
the female life expectancy advantage has again increased 
by two years. This does not mean, however, that the female 
disadvantage in the remaining burden of HIV mortality has 
been fully rectified because women still lose more adult 
life-years to HIV/AIDS than men. 
Figure 5. Contribution of groups of causes of death 
to life expectancy gains at age 15 
since the roll-out of antiretroviral treatments 
(uMkhanyakude, 2001-2014)
B. Masquelier & G. Reniers, Population & Societies n° 554, INED, April 2018.
Sources: Reniers et al. [7].
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